Simplex Trading, LLC Lipocine Inc. Transaction History

Simplex Trading, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 02, 2021	SELL	$1.2 - $1.69 $31,845 - $44,849	-26,538 Closed	0 $0
Q3 2020 Oct 14, 2020	BUY	$1.21 - $2.23 $32,110 - $59,179	26,538 New	26,538 $37,000
Q2 2020 Jul 13, 2020	SELL	$0.42 - $1.26 $42 - $126	-100 Closed	0 $0
Q1 2020 Apr 29, 2020	SELL	$0.32 - $0.77 $224 - $539	-700 Reduced 87.5%	100 $0
Q4 2019 Feb 05, 2020	BUY	$0.32 - $3.15 $256 - $2,520	800 New	800 $0
Q3 2019 Oct 15, 2019	SELL	$1.79 - $3.33 $6,873 - $12,787	-3,840 Closed	0 $0
Q2 2019 Jul 26, 2019	BUY	$1.43 - $2.32 $4,873 - $7,906	3,408 Added 788.89%	3,840 $7,000
Q1 2019 Apr 18, 2019	BUY	$1.46 - $2.33 $630 - $1,006	432 New	432 $0
Q4 2018 Jan 16, 2019	SELL	$1.07 - $1.63 $1,570 - $2,392	-1,468 Closed	0 $0
Q3 2018 Oct 23, 2018	SELL	$1.31 - $1.63 $4,434 - $5,517	-3,385 Reduced 69.75%	1,468 $2,000
Q2 2018 Jul 30, 2018	BUY	$1.06 - $1.78 $1,234 - $2,073	1,165 Added 31.59%	4,853 $6,000
Q1 2018 Apr 26, 2018	SELL	$1.18 - $3.46 $6,871 - $20,147	-5,823 Reduced 61.22%	3,688 $5,000
Q4 2017 Jan 10, 2018	BUY	$3.36 - $4.35 $31,956 - $41,372	9,511	9,511 $32,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $433M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.